Therapeutic CD47 antibodies
Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.
1. A method of treating a susceptible cancer in a human comprising administering thereto an effective amount of a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds CD47, wherein said monoclonal antibody, or antigen-binding fragment thereof, comprises three light chain complementarity determining regions (LCDRs 1-3) and three heavy chain complementarity determining regions (HCDRs 1-3), wherein:
LCDR 1 comprises the amino acid sequence
(SEQ ID NO: 1)
RSSQSLVHSNGNTYLH
LCDR 2 comprises the amino acid sequence
(SEQ ID NO: 2)
KVSYRFS;
and
LCDR 3 comprises the amino acid sequence
(SEQ ID NO: 3)
SQNTHVPRT;
HCDR1 comprises the amino acid sequence
(SEQ ID NO: 4)
GYTFTNYYVF;
HCDR 2 comprises the amino acid sequence
(SEQ ID NO: 5)
DINPVNGDTNFNEKFKN;
and
HCDR 3 comprises the amino acid sequence
(SEQ ID NO: 6)
GGYTMDY,
and which exhibits cytotoxic activity.
2. The method of claim 1 , wherein said monoclonal antibody, or antigen-binding fragment thereof, is chimeric or humanized.
3. The method of claim 1 , wherein said monoclonal antibody, or antigen-binding fragment thereof, specifically binds human, rat, mouse, and pig CD47.
4. The method of claim 1 , wherein said monoclonal antibody, or antigen-binding fragment thereof, comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR and said HCVR comprise, respectively, amino acid sequences selected from the group consisting of:
SEQ ID NO:7 and SEQ ID NO:57;
SEQ ID NO:8 and SEQ ID NO:58;
SEQ ID NO:9 and SEQ ID NO:59;
SEQ ID NO:10 and SEQ ID NO:60;
SEQ ID NO:11 and SEQ ID NO:61;
SEQ ID NO:12 and SEQ ID NO:62;
SEQ ID NO:13 and SEQ ID NO:63;
SEQ ID NO:14 and SEQ ID NO:64;
SEQ ID NO:15 and SEQ ID NO:65;
SEQ ID NO:16 and SEQ ID NO:66;
SEQ ID NO:17 and SEQ ID NO:67;
SEQ ID NO:18 and SEQ ID NO:68;
SEQ ID NO:19 and SEQ ID NO:69;
SEQ ID NO:20 and SEQ ID NO:70;
SEQ ID NO:21 and SEQ ID NO:71;
SEQ ID NO:22 and SEQ ID NO:72;
SEQ ID NO:23 and SEQ ID NO:73;
SEQ ID NO:24 and SEQ ID NO:74;
SEQ ID NO:25 and SEQ ID NO:75;
SEQ ID NO:26 and SEQ ID NO:76;
SEQ ID NO:27 and SEQ ID NO:77;
SEQ ID NO:28 and SEQ ID NO:78;
SEQ ID NO:29 and SEQ ID NO:79;
SEQ ID NO:30 and SEQ ID NO:80; and
SEQ ID NO:31 and SEQ ID NO:81.
5. The method of claim 1 , wherein said susceptible cancer is selected from the group consisting of a leukemia, a lymphoma, ovarian cancer, breast cancer, endometrial cancer, colon cancer, rectal cancer, bladder cancer, lung cancer, bronchial cancer, bone cancer, prostate cancer, pancreatic cancer, liver and bile duct cancer, esophageal cancer, renal cancer, thyroid cancer, head and neck cancer, testicular cancer, glioblastoma, astrocytoma, melanoma, and leiomyosarcoma.
6. The method of claim 5 , wherein said leukemia is selected from the group consisting of acute lymphocytic (lymphoblastic) leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and chronic myeloid leukemia.
7. The method of claim 1 , wherein said monoclonal antibody, or antigen-binding fragment thereof, which exhibits cytotoxic activity, increases phagocytosis of cells of said susceptible cancer.
8. The method of claim 7 , wherein said monoclonal antibody, or antigen-binding fragment thereof, which exhibits cytotoxic activity and increases phagocytosis of cells of said susceptible cancer, inhibits CD47 binding to SIRPalpha.
9. The method of claim 1 , wherein said monoclonal antibody, or antigen-binding fragment thereof, which exhibits cytotoxic activity, is directly toxic to cells of said susceptible cancer.